Clinical Trial VICCBMT1129


A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX for the Treatment of Patients with Moderate to Severe Chronic Graft vs Host Disease

Principal Investigator(s)

Madan Jagasia


  • Protocol No. VICCBMT1129
  • Open Date: 11/17/2011
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: To compare the efficacy of ECP as determined by the incremental improvement in cGvHD according to National Institutes of Health (NIH) Consensus Response Criteria versus a control population.
  • Disease Sites: Supportive Care; Lymphoma
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics; Therapy (NOS)
  • Drugs: UVADEX (methoxsalen)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01380535
  • Secondary Protocol No: 10-005



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.